Literature DB >> 26091712

Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism.

F A Klok1, C Niemann2, C Dellas3, G Hasenfuß2, S Konstantinides1, M Lankeit4,5.   

Abstract

Bleeding-prediction scores may help guiding management of patients with pulmonary embolism (PE), although no such score has been validated. We aimed to externally validate and compare two bleeding-prediction scores for venous thromboembolism to three scores developed for patients with atrial fibrillation in a real-world cohort of PE patients. We performed a prospective observational cohort study in 448 consecutive PE patients who were treated with heparins followed by vitamin-K-antagonists. The Kuijer, RIETE, HEMORR2HAGES, HAS-BLED and ATRIA scores were assessed at baseline. All patients were followed for the occurrence of major bleeding over a 30-day period. The accuracies of both the overall, original 3-level and newly defined optimal 2-level outcome of the scores were evaluated and compared, both for the 30-day period as well as for bleeding occurring in versus after the first week of treatment. 20 of 448 patients suffered major bleeding resulting in a cumulative incidence of 4.5 % (95 % CI 2.5-6.5). The predictive power of all five scores for bleeding was poor (c-statistics 0.57-0.64), both for the 3-level and 2-level score outcomes. No individual score was found to be superior. The HAS-BLED score had a good c-statistic for bleedings occurring after the first week of treatment (0.75, 95 % CI 0.47-1.0). Current available scoring systems have insufficient accuracy to predict overall anticoagulation-associated bleeding in patients treated for acute PE. To optimally target bleeding-prevention strategies, the development of a high quality PE-specific risk score is urgently needed.

Entities:  

Keywords:  Atrial fibrillation; Bleeding; Prevention; Pulmonary embolism; Risk score

Mesh:

Substances:

Year:  2016        PMID: 26091712     DOI: 10.1007/s11239-015-1239-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  26 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.

Authors:  Margaret C Fang; Alan S Go; Yuchiao Chang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Daniel E Singer
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

3.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

4.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

5.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

6.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.

Authors:  P M Kuijer; B A Hutten; M H Prins; H R Büller
Journal:  Arch Intern Med       Date:  1999-03-08

7.  Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial.

Authors:  David B Matchar; Gregory P Samsa; Stuart J Cohen; Eugene Z Oddone; Annette E Jurgelski
Journal:  Am J Med       Date:  2002-07       Impact factor: 4.965

8.  Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study.

Authors:  N Riva; M Bellesini; M N D Di Minno; N Mumoli; F Pomero; M Franchini; C Fantoni; R Lupoli; B Brondi; V Borretta; C Bonfanti; W Ageno; F Dentali
Journal:  Thromb Haemost       Date:  2014-06-05       Impact factor: 5.249

9.  Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.

Authors:  Ramón Lecumberri; Ana Alfonso; David Jiménez; Carmen Fernández Capitán; Paolo Prandoni; Philip S Wells; Gemma Vidal; Giovanni Barillari; Manuel Monreal
Journal:  Thromb Haemost       Date:  2013-07-11       Impact factor: 5.249

10.  The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment.

Authors:  Judith Kooiman; Nadja van Hagen; Antonio Iglesias Del Sol; Erwin V Planken; Gregory Y H Lip; Felix J M van der Meer; Suzanne C Cannegieter; Frederikus A Klok; Menno V Huisman
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

View more
  8 in total

Review 1.  Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis.

Authors:  Corinne Frere; Carme Font; Francis Esposito; Benjamin Crichi; Philippe Girard; Nicolas Janus
Journal:  Support Care Cancer       Date:  2021-10-06       Impact factor: 3.359

2.  Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.

Authors:  Amir Kuperman; Raquel López-Reyes; Lopez-Saez Juan Bosco; Alicia Lorenzo; Bascuñana José; Dominique Farge Bancel; María Alfonso; Marina Lumbierres; Galia Stemer; Manuel Monreal Bosch; Andrei Braester
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

3.  [Anticoagulation strategies in patients with deep vein thrombosis and pulmonary artery embolisms].

Authors:  P W Radke; M Möckel
Journal:  Herz       Date:  2018-02       Impact factor: 1.443

4.  Clinical characteristics, time course, and outcomes of major bleeding according to bleeding site in patients with venous thromboembolism.

Authors:  Behnood Bikdeli; Fares Moustafa; José Antonio Nieto; Alfred I Lee; Nuria Ruíz-Giménez; Alicia Lorenzo; Sebastian Schellong; Silvia Soler; Salvador Ortíz; Mª Del Valle Morales; Marijan Bosevski; Olga Gavín; Gregory Y H Lip; Manuel Monreal
Journal:  Thromb Res       Date:  2022-01-14       Impact factor: 3.944

5.  Correlation of plasma coagulation tests and fibrinogenClauss with rotational thromboelastometry parameters and prediction of bleeding in dogs.

Authors:  Nathalie M Enk; Annette P N Kutter; Claudia Kuemmerle-Fraune; Nadja E Sigrist
Journal:  J Vet Intern Med       Date:  2018-12-11       Impact factor: 3.333

6.  Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism.

Authors:  Frederikus A Klok; Emilie Presles; Cecile Tromeur; Stefano Barco; Stavros V Konstantinides; Olivier Sanchez; Gilles Pernod; Leela Raj; Philippe Robin; Pierre-Yves Le Roux; Clément Hoffman; Solen Mélac; Laurent Bertoletti; Philippe Girard; Silvy Laporte; Patrick Mismetti; Guy Meyer; Christophe Leroyer; Francis Couturaud
Journal:  Res Pract Thromb Haemost       Date:  2019-05-25

7.  Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.

Authors:  Paul L den Exter; Scott C Woller; Helia Robert-Ebadi; Camila Masias; Pierre-Emmanuel Morange; David Castelli; John-Bjarne Hansen; Geert-Jan Geersing; Deborah M Siegal; Kerstin de Wit; Frederikus A Klok
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

8.  Predictors for Prognosis in Patients With Nonfatal Pulmonary Embolism: A Registry-Based Cohort Study.

Authors:  Marijan Bosevski; Gorjan Krstevski; Atanas Gjorgievski; Irena Mitevska; Elizabeta Srbinovska Kostovska
Journal:  Clin Appl Thromb Hemost       Date:  2018-07-26       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.